Hayley McDaid, PhD
New York, New York
Associate Professor, Department of Medicine (Oncology)
Associate Professor, Department of Molecular Pharmacology
Albert Einstein College of Medicine
New York, New York
Identifying targeted therapies and novel combination approaches to decrease drug resistance and improve outcomes for patients with triple-negative breast cancer.
Therapeutics such as Taxol are indicated for first-line treatment of patients with triple-negative breast cancer (TNBC) and other types of breast cancer. While many patients experience good outcomes to this treatment, some patients are resistant to therapy or have an incomplete response, eventually relapsing after a period of remission. In addition, some patients develop toxicities or experience long-term, debilitating side effects. The BCRF research led by Drs. McDaid and Horwitz is focused on defining the fate of cancer cells that survive anti-cancer therapy, specifically investigating the causes of resistance to drugs like Taxol. They have synthesized novel molecules that work like Taxol but are more effective at killing breast cancer cells in laboratory models. They are investigating the therapeutic efficacy of these molecules with the long-term goal of developing potent, less toxic Taxol-like drugs for use in advanced disease.
One of the synthesized drugs has shown promising anti-tumor efficacy and a low toxicity profile and they are now evaluating its mechanism of action. In other studies, they are examining cellular senescence—an underlying cause of relapse after chemotherapy. They showed that while senescent cancer cells are damaged and do not divide, they do produce inflammatory proteins that can promote the growth of neighboring non-damaged tumor cells thereby leading to treatment resistance, recurrence, or metastasis.
The team will continue investigating potential drug candidates for treatment of TNBC that both strongly induce tumor cell death and have a low risk of inducing cellular dormancy. In addition, they will delineate the molecular signatures of senescence that can be exploited to develop new drugs to eradicate these tumor cells.
Dr. Hayley McDaid received her PhD from the Queens University of Belfast, where she characterized the role of the cAMP-dependent protein kinase A signaling pathway in breast and ovarian cancer. These studies pioneered her present-day interest in targeted therapies, pharmacogenomics and rationally designed drug combinations.
Dr. McDaid's broad research theme in breast cancer is focused on investigating molecular mechanisms of action and resistance to novel therapeutics. She is interested in defining the ‘circuitry’ of breast cancer in the different molecular subtypes of triple negative tumors; and mechanisms by which tumors counteract the effects of therapy. As part of this focus, Dr. McDaid has been studying chemotherapy-mediated senescence, a type of growth arrest that is increasingly perceived as a deleterious outcome of treatment. Together with colleagues, she is interested in chemical-biological approaches to minimize the risk of developing senescence during treatment.
When you give to BCRF, you're funding critical hours in the lab. More time for research means longer, healthier lives for the ones we love.